Sökning: onr:"swepub:oai:DiVA.org:liu-149494" >
Smoking reduces the...
Smoking reduces the efficacy of belimumab in mucocutaneous lupus.
-
- Parodis, Ioannis (författare)
- Karolinska Institutet,Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden
-
- Gomez, Alvaro (författare)
- Karolinska Institutet,Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden
-
- Frodlund, Martina (författare)
- Linköping University,Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Reumatologiska kliniken i Östergötland
-
visa fler...
-
- Jönsen, Andreas (författare)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Zickert, Agneta (författare)
- Karolinska Institutet,Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden
-
- Sjöwall, Christoffer, 1975- (författare)
- Linköping University,Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Reumatologiska kliniken i Östergötland
-
- Bengtsson, Anders A. (författare)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Gunnarsson, Iva (författare)
- Karolinska Institutet,Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2018-07-09
- 2018
- Engelska.
-
Ingår i: Expert Opinion on Biological Therapy. - : Informa Healthcare. - 1471-2598 .- 1744-7682. ; 18:8, s. 911-920
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
http://liu.diva-port...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVES: Recently, we demonstrated a negative impact of smoking on belimumab efficacy in patients with systemic lupus erythematosus (SLE). Here, we particularly investigated clinical effects of belimumab and a potential impact of smoking in mucocutaneous and articular SLE.METHODS: We surveyed 62 SLE patients treated between 2011 and 2017. Evaluation included the mucocutaneous descriptors of SLEDAI-2K (rash, alopecia, mucosal ulcers; mcSLEDAI-2K), CLASI, the arthritis SLEDAI-2K descriptor (arSLEDAI-2K) and the 28-joint count.RESULTS: mcSLEDAI-2K and CLASI activity decreased from baseline to month 6 and 12 (P<0.001 for all). No worsening in CLASI damage was observed. Current or previous smokers displayed a higher probability of unchanged/worsened mcSLEDAI-2K compared to never smokers (OR: 6.4; 95% CI: 1.5-27.4; P=0.012), also after adjustment for antimalarial agents. arSLEDAI-2K scores had decreased at month 6 (P<0.001) and 12 (P<0.001). Likewise, tender and swollen 28-joint counts had improved at month 6 (P=0.010 and P<0.001, respectively) and 12 (P=0.001 for both). We observed no impact of smoking on belimumab efficacy in articular SLE.CONCLUSION: We observed a negative impact of smoking on the efficacy of belimumab in mucocutaneous SLE. In contrast, no impact of smoking on belimumab efficacy was seen in patients with articular manifestations.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Nyckelord
- belimumab
- biological agents
- drug efficacy
- rheumatology
- systemic lupus erythematosus
- Belimumab
- biological agents
- drug efficacy
- rheumatology
- systemic lupus erythematosus
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas